TNGX
Tango Therapeutics, Inc. NASDAQ Listed Sep 3, 2020$23.51
After hrs
$23.48
+2.00%
Mkt Cap $2.7B
52w Low $1.03
82.1% of range
52w High $28.41
50d MA $20.14
200d MA $11.67
P/E (TTM)
-24.1x
EV/EBITDA
-8.7x
P/B
7.0x
Debt/Equity
0.1x
ROE
-29.3%
P/FCF
-7.4x
RSI (14)
—
ATR (14)
—
Beta
1.31
50d MA
$20.14
200d MA
$11.67
Avg Volume
3.4M
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
100 Binney Street · Boston, MA 02142 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | -0.31 | -0.29 | +6.5% | 16.83 | -0.6% | +0.7% | -2.3% | -2.0% | +1.0% | +1.9% | — |
| Nov 4, 2025 | AMC | 0.01 | 0.13 | +1200.0% | 8.01 | +0.6% | -6.2% | +0.0% | -1.7% | -1.0% | +4.6% | — |
| Aug 5, 2025 | AMC | -0.35 | -0.35 | +0.0% | 6.91 | +0.0% | -5.9% | -4.3% | -4.3% | -7.2% | -2.2% | — |
| May 12, 2025 | AMC | -0.34 | -0.36 | -5.9% | 1.31 | +0.8% | +6.9% | -1.5% | +16.0% | +14.5% | +74.8% | — |
| Feb 27, 2025 | AMC | -0.32 | -0.35 | -9.4% | 2.18 | -0.5% | -5.0% | -12.8% | -15.6% | -4.1% | -3.2% | — |
| Nov 6, 2024 | AMC | -0.34 | -0.27 | +20.6% | 3.24 | +1.9% | -12.7% | -9.0% | +4.3% | +3.4% | +9.9% | — |
| Aug 7, 2024 | AMC | -0.34 | -0.24 | +29.4% | 8.72 | +3.6% | +2.2% | -2.5% | -2.5% | +3.8% | +6.7% | — |
| May 8, 2024 | AMC | -0.31 | -0.35 | -12.9% | 7.91 | -1.1% | -1.8% | -10.1% | -7.6% | -3.9% | -1.4% | — |
| Mar 18, 2024 | AMC | -0.28 | -0.32 | -14.3% | 8.39 | -1.0% | -2.9% | +1.3% | -2.0% | -7.9% | -9.1% | — |
| Nov 8, 2023 | AMC | -0.34 | -0.23 | +32.4% | 8.94 | +1.5% | -6.0% | -6.5% | -15.3% | -12.8% | -19.1% | — |
| Aug 7, 2023 | AMC | -0.35 | -0.23 | +34.3% | 3.44 | +0.3% | +11.3% | +127.0% | +90.1% | +118.3% | +103.2% | — |
| May 9, 2023 | AMC | -0.36 | -0.32 | +11.1% | 3.66 | +0.5% | +5.5% | +1.1% | -1.9% | +3.0% | -1.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | Stifel | Maintains | Buy → Buy | — | $25.77 | $26.32 | +2.1% | +2.2% | -2.4% | -14.4% | -16.1% | -18.6% |
| Mar 11 | Mizuho | Maintains | Outperform → Outperform | — | $16.50 | $16.32 | -1.1% | +3.0% | +3.9% | +4.8% | +8.4% | +13.2% |
| Mar 9 | Stifel | Maintains | Buy → Buy | — | $16.95 | $16.95 | +0.0% | -2.9% | -2.7% | +0.2% | +1.2% | +2.1% |
| Mar 6 | Wedbush | Maintains | Outperform → Outperform | — | $16.83 | $16.73 | -0.6% | +0.7% | -2.3% | -2.0% | +1.0% | +1.9% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.83 | $16.73 | -0.6% | +0.7% | -2.3% | -2.0% | +1.0% | +1.9% |
| Mar 6 | Guggenheim | Maintains | Buy → Buy | — | $16.83 | $16.73 | -0.6% | +0.7% | -2.3% | -2.0% | +1.0% | +1.9% |
| Feb 6 | Guggenheim | Maintains | Buy → Buy | — | $11.95 | $12.47 | +4.4% | +4.7% | +7.9% | +6.2% | +5.5% | +6.0% |
| Jan 16 | Piper Sandler | Maintains | Overweight → Overweight | — | $11.69 | $11.48 | -1.8% | +11.3% | +7.0% | +7.0% | +5.6% | +0.2% |
| Nov 18 | B. Riley Securities | Maintains | Buy → Buy | — | $7.98 | $7.77 | -2.6% | +0.3% | +3.9% | +11.5% | +25.7% | +29.4% |
| Oct 24 | Guggenheim | Maintains | Buy → Buy | — | $7.53 | $7.84 | +4.1% | -0.4% | +3.2% | +3.5% | +4.0% | +5.8% |
| Aug 6 | Guggenheim | Maintains | Buy → Buy | — | $6.91 | $6.91 | +0.0% | -5.9% | -4.3% | -4.3% | -7.2% | -2.2% |
| Apr 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.41 | $1.44 | +2.1% | -5.0% | -2.1% | -9.2% | -8.5% | -2.1% |
| Dec 5 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.52 | $3.48 | -1.1% | -1.4% | -3.7% | -8.8% | -6.0% | -11.9% |
| Nov 11 | B. Riley Securities | Maintains | Buy → Buy | — | $2.95 | $2.92 | -1.0% | +14.6% | +13.6% | +20.7% | +32.9% | +30.5% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.83 | $2.90 | +2.5% | +4.2% | +19.4% | +18.4% | +25.8% | +38.5% |
| Nov 7 | Guggenheim | Maintains | Buy → Buy | — | $3.24 | $3.30 | +1.9% | -12.7% | -9.0% | +4.3% | +3.4% | +9.9% |
| Oct 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.93 | $5.97 | +0.7% | -0.2% | +1.2% | -3.7% | -8.3% | -13.2% |
| Sep 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.16 | $9.00 | -1.7% | -0.8% | +5.8% | +9.2% | +14.6% | +4.9% |
| Aug 8 | Wedbush | Maintains | Outperform → Outperform | — | $8.72 | $9.03 | +3.6% | +2.2% | -2.5% | -2.5% | +3.8% | +6.7% |
| Jul 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.88 | $8.87 | -0.1% | +8.2% | +3.9% | +8.2% | +12.2% | +12.8% |
| May 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.91 | $6.96 | +0.7% | -0.9% | -2.3% | -3.6% | +0.1% | +1.3% |
| May 28 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $6.91 | $6.96 | +0.7% | -0.9% | -2.3% | -3.6% | +0.1% | +1.3% |
| May 24 | Guggenheim | Maintains | Buy → Buy | — | $7.09 | $7.07 | -0.3% | -2.5% | -3.4% | -4.8% | -6.1% | -2.4% |
| May 24 | Barclays | Maintains | Overweight → Overweight | — | $7.09 | $7.07 | -0.3% | -2.5% | -3.4% | -4.8% | -6.1% | -2.4% |
| May 23 | Wedbush | Maintains | Outperform → Outperform | — | $7.39 | $6.71 | -9.2% | -4.1% | -6.5% | -7.3% | -8.7% | -9.9% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.91 | $7.82 | -1.1% | -1.8% | -10.1% | -7.6% | -3.9% | -1.4% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.15 | $8.38 | +2.8% | +4.3% | +0.9% | -5.2% | -6.4% | -7.9% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.54 | $6.93 | +6.0% | +14.8% | +6.9% | +5.5% | +4.6% | +8.9% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.44 | $3.45 | +0.3% | +11.3% | +127.0% | +90.1% | +118.3% | +103.2% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.78 | $3.80 | +0.5% | -0.5% | +6.3% | +3.7% | +4.5% | +15.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Crystal Adam | President, R&D | Sell | 1,100 | $22.00 | $24K | 115,743 | -2.40% | — |
| May 1, 2026 | Crystal Adam | President, R&D | Sell | 25,900 | $21.19 | $549K | 116,843 | -2.40% | — |
8-K
Tango Therapeutics, Inc. -- 8-K Filing
Tango Therapeutics extended the post-termination exercise period for departed executive Ms. Beckman's vested stock options through August 2026, providing her additional time to exercise her equity awards.
May 8
8-K
Unknown — 8-K Filing
A new executive compensation package signals leadership continuity, but the $540,000 salary and 40% bonus structure indicate moderate executive costs that shouldn't meaningfully impact shareholder value.
Apr 15
8-K
Tango Therapeutics, Inc. -- 8-K Filing
Tango Therapeutics reported 2025 year-end financial results and outlined execution priorities for 2026, emphasizing portfolio progress in precision cancer medicine development.
Mar 5
Data updated apr 27, 2026 5:11am
· Source: massive.com